Document Detail


Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors.
MedLine Citation:
PMID:  24352938     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
The functional properties of the adoptive immune response mediated by effector T lymphocytes are decisively regulated by their T-cell receptors (TCRs). Transfer of genes encoding target antigen-specific receptors enables polyclonal T cells to redirect toward cancer cells and virally infected cells expressing those defined antigens. Using this technology, a large population of redirected T cells displaying uniform therapeutic properties has been produced, powerfully advancing their clinical application as "cellular drugs" for adoptive immunotherapy against cancer. Clinically, anticancer adoptive immunotherapy using these genetically engineered T cells has an impressive and proven track record. Notable examples include the dramatic benefit of chimeric antigen receptor gene-modified T cells redirected towards B-cell lineage antigen CD19 in patients with chronic lymphocytic leukemia, and the impressive outcomes in the use of TCR gene-modified T cells redirected towards NY-ESO-1, a representative cancer-testis antigen, in patients with advanced melanoma and synovial cell sarcoma. In this review, we briefly overview the current status of this treatment option in the context of hematological malignancy, and discuss a number of challenges that still pose an obstacle to the full effectiveness of this strategy.
Authors:
Hiroshi Fujiwara
Related Documents :
24599748 - Myc proteins promote neuronal differentiation by controlling the mode of progenitor cel...
15897328 - Bone marrow stem cell transplantation for cardiac repair.
25068508 - 177lu-dota-hh1, a novel anti-cd37 radio-immunoconjugate: a study of toxicity in nude mice.
23684068 - T-cell receptor ligation causes wiskott-aldrich syndrome protein degradation and f-acti...
23498798 - Induction of cd4(+)cd25(+) t cells and control of cardiac allograft rejection by cd40/c...
6975648 - Coexistence of a primary immunodeficiency disorder and hodgkin's disease: evidence agai...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-12-19
Journal Detail:
Title:  International journal of hematology     Volume:  -     ISSN:  1865-3774     ISO Abbreviation:  Int. J. Hematol.     Publication Date:  2013 Dec 
Date Detail:
Created Date:  2013-12-19     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9111627     Medline TA:  Int J Hematol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effectiveness of first line use of recombinant IL-1RA treatment in steroid naïve systemic juvenile i...
Next Document:  Polarization distance: a framework for modelling object detection by polarization vision systems.